Search
Relay Therapeutics Inc
RLAYAdd to Watchlist
18.650USD
+0.890+5.01%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
3.24BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.01%
5 Days
+0.48%
1 Month
+21.90%
6 Months
+128.00%
Year to Date
+120.45%
1 Year
+413.77%
Key Figures
17.880Open
18.670High
3.17MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.83%Turnover Ratio
17.760Prev. Close
17.680Low
44.74MTurnover
LossP/E Static
5.72P/B
0.00%Div Yield TTM
-36.39%ROA
17.32052wk High
0.92Volume Ratio
-337.71MNet Profit
173.87MShares
-1.5634EPS TTM
1.76Beta
-40.01%ROE
2.91052wk Low
5.57%Amplitude
100.00%Gross Margin
3.24BMarket Cap
5.14Reward/Risk
4.31%Risk Rate
TradingKey Stock Score of Relay Therapeutics Inc
Currency: USD Updated: 2026-07-02Key Insights
Relay Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 35 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 24.82.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Relay Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Relay Therapeutics Inc Highlights
StrengthsRisks
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Growing
The company is in a growing phase, with the latest annual income totaling USD 15.36M.
Undervalued
The company’s latest PE is -11.93, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 194.30M shares, decreasing 1.84% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 507.28K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.00.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
24.818
Target Price
+39.74%
Upside Space
Relay Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Relay Therapeutics Inc Info
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Ticker SymbolRLAY
CompanyRelay Therapeutics Inc
CEOPatel (Sanjiv K)
Websitehttps://relaytx.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Relay Therapeutics Inc (RLAY)?
The current price of Relay Therapeutics Inc (RLAY) is 18.65.
What is the symbol of Relay Therapeutics Inc?
The ticker symbol of Relay Therapeutics Inc is RLAY.
What is the 52-week high of Relay Therapeutics Inc?
The 52-week high of Relay Therapeutics Inc is 17.32.
What is the 52-week low of Relay Therapeutics Inc?
The 52-week low of Relay Therapeutics Inc is 2.91.
What is the market capitalization of Relay Therapeutics Inc?
The market capitalization of Relay Therapeutics Inc is 4.02B.
Is Relay Therapeutics Inc (RLAY) currently rated as Buy, Hold, or Sell?
According to analysts, Relay Therapeutics Inc (RLAY) has an overall rating of Buy, with a price target of 24.82.
What is the Earnings Per Share (EPS TTM) of Relay Therapeutics Inc (RLAY)?
The Earnings Per Share (EPS TTM) of Relay Therapeutics Inc (RLAY) is -1.61.